サイト内検索


登録済み会員ログイン




未登録の方はこちらから登録できます。
新規会員登録


ご利用案内

ご利用案内


連絡先

TEL.03-5812-5270
FAX.03-3831-0495
E-mail:info@spi-information.com


関連サイト・サービス

市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。

シードプランニング

世界の医療・医薬品産業レポートのデータベースサービスは、sekairyo.comにてご利用いただけます。

sekairyo.com

医療従事者へのあらゆる形態の調査は、メドサークルにお任せ下さい。

メドサークル


セキュリティについて

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。


COPD Therapeutics in Asia-Pacific Markets to 2023 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Novel Therapies

アジア太平洋市場における2023年までのCOPD治療‐有病者数の増加、認知度向上、および新規治療薬の上市が成長を促す

レポート概要

慢性閉塞性肺疾患(COPD)は、正常な呼吸を妨害する気流の閉塞を特徴とする肺疾患の大群を指す用語です。これは高齢者で最も頻繁に発生しますが、中高年齢人口にも影響を及ぼします。COPDは、世界的に慢性罹患率および死亡率の主因です。多くの人々はこの病気に何年も苦しんでおり、最終的にはそれ、またはその合併症により死亡します。それは相当な経済的および社会的負担となることを意味します。COPDの負担は世界的に、疾患リスク要因の継続的な曝露と喫煙者の増加により、今後数十年間に増加することが予測されています。喫煙の増加は、その状態で生活する人の数が増えることにつながります。COPDに起因する死亡率のシェアは、心臓病や脳卒中などの他の慢性疾患と比較して、今後数十年間に増加すると予想されます。市販製品は、気管支拡張剤の組み合わせ、気管支拡張剤および吸入ステロイド(ICS)の組み合わせ、気管支拡張剤の単独療法およびPDE-4阻害剤を含む幅広い治療選択肢から成ります。しかしながら市場は、気管支拡張剤およびICS療法から、標的化およびトリプルコンビネーション薬物治療に移行しており、徐々に変化しつつあります。同市場は、最近上市された製品や、現在のマーケットリーダーを補完し、より幅広い治療オプションを提供する新薬の承認によって推進される見込みです。

■調査範囲

  • アジア太平洋のCOPD市場は、2016年の38億ドルからCAGR 8.7%で推移して、2023年には67億ドルに達する見込みです。
  • 気管支拡張薬およびICS治療薬がCOPD市場を独占していますが、安全性や有効性に関して、アンメットニーズが存在します。開発中の薬剤はこのアンメットニーズに対処するでしょうか?
  • ブランド薬は継続的に成長するでしょうか、ジェネリックの競合に直面するでしょうか?
  • ブランド薬は、今後上市されるパイプライン製品にどのような影響を受けるでしょうか?
  • パイプラインは、COPDにおいて確立したものや新規ファースト・イン・クラス製品など、広範な分子タイプや分子ターゲットを含みます。
    ➣ パイプラインにおいて、どの分子ターゲットが最も多いでしょうか?
    ➣ パイプラインは、COPD患者に対する限られた標的治療薬に関するアンメットニーズに対処するでしょうか?
    ➣ どのファースト・イン・クラスのトリプルコンビネーションがCOPD市場に参入するでしょうか、またそれらは既存治療薬とどの様に競合するでしょうか?
  • 様々な市場促進および抑制要因が市場に影響を及ぼす見込みです。
    ➣ アジア太平洋地域において、何がプレミアム価格の治療薬の使用を制限するでしょうか?
    ➣ 市場成長を最も促す要因は何でしょうか?

レポート詳細

目次

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology and Pathophysiology
2.4.1 Pathophysiology
2.5 Diagnosis
2.6 Disease Stages
2.7 Prognosis
2.8 Treatment Options
2.8.1 Treatment Algorithm

3 Marketed Products
3.1 Overview
3.2 Bronchodilator Combination Therapy
3.2.1 Brimica/Duaklir Genuair (aclidinium/formoterol) - AstraZeneca
3.2.2 Spiolto/Stiolto Respimat (tiotropium/olodaterol) - Boehringer Ingelheim
3.2.3 Ultibro (glycopyrronium/indacaterol) - Novartis
3.2.4 Anoro Ellipta (umeclidinium/vilanterol) - GlaxoSmithKline/Theravance
3.2.5 Combivent (ipratropium/albuterol) - Boehringer Ingelheim
3.3 Bronchodilator and Inhaled Corticosteroid Combination Therapy
3.3.1 Symbicort (budesonide/formoterol) - AstraZeneca
3.3.2 Seretide/Advair/Adoair (salmeterol/fluticasone) - GlaxoSmithKline
3.3.3 Relvar/Breo (fluticasone and vilanterol) - GlaxoSmithKline/Theravance
3.4 Bronchodilator Monotherapy
3.4.1 Spiriva (tiotropium) - Boehringer Ingelheim
3.4.2 Foradil (formoterol) - Novartis
3.4.3 Onbrez/Arbeela/Arcapta (indacaterol) - Novartis
3.4.4 Seebri /Tovanor (glycopyrronium) - Novartis
3.4.5 Striverdi Respimat (olodaterol) - Boehringer Ingelheim
3.5 Alternative therapy
3.5.1 Daxas/Daliresp (roflumilast) - Nycomeds
3.5.2 Marketed Products Heatmap

4 Pipeline Analysis
4.1 Overview
4.2 Pipeline Distribution by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline Distribution by Molecular Target
4.4 Promising Pipeline Candidates
4.4.1 Mepolizumab - GlaxoSmithKline
4.4.2 Benralizumab - AstraZeneca and MedImmune
4.4.3 PT003 - AstraZeneca/Pearl Therapeutics
4.4.4 PT010 - AstraZeneca/Pearl Therapeutics
4.4.5 Fluticasone Furoate, Umeclidinium Bromide and Vilanterol Trifenatate -GlaxoSmithKline
4.4.6 CHF-5993 (beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide) - Chiesi Farmaceutici S.p.A.
4.5 Heatmap for Pipeline Products
4.6 Product Competitiveness Framework

5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecule Type
5.1.3 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Size
5.2.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Phase
5.2.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Phase
5.3 Clinical Trial Duration
5.3.1 Clinical Trial Duration by Molecule Type
5.3.2 Clinical Trial Duration by Molecular Target
5.4 Competitive Clinical Trials Metrics Analysis

6 Multi-scenario Forecast
6.1 Geographical Markets
6.2 Asia-Pacific Market
6.3 India
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Australia
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 South Korea
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size
6.7 Japan
6.7.1 Treatment Usage Patterns
6.7.2 Annual Cost of Therapy
6.7.3 Market Size

7 Drivers and Barriers
7.1 Drivers
7.1.1 Active Pipeline
7.1.2 Promising Late-Stage Pipeline Products Can Change Treatment Paradigm
7.1.3 Increasing Awareness of COPD
7.1.4 Aging Population
7.2 Barriers
7.2.1 Sales Erosion by Generics
7.2.2 Growing Competition
7.2.3 Low Diagnosis Rates

8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 Deals by Region and Value
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.1.4 Key Licensing Deals
8.2 Co-development Deals
8.2.1 Deals by Region and Value
8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.2.4 Key Co-development Deals

9 Appendix
9.1 All Pipeline Drugs by Stage of Development
9.1.1 Discovery
9.1.2 Preclinical
9.1.3 Phase I
9.1.4 Phase II
9.1.5 Phase III
9.1.6 Pre-registration
9.2 Market Forecasts to 2023
9.2.1 Asia-Pacific
9.2.2 India
9.2.3 China
9.2.4 Australia
9.2.5 South Korea
9.2.6 Japan
9.3 Bibliography
9.4 Abbreviations
9.5 Research Methodology
9.5.1 Secondary Research
9.5.2 Marketed Product Profiles
9.5.3 Late-Stage Pipeline Candidates
9.5.4 Comparative Efficacy and Safety Heatmap for Marketed and Pipeline Products
9.5.5 Product Competitiveness Framework
9.5.6 Pipeline Analysis
9.5.7 Forecasting Model
9.5.8 Deals Data Analysis
9.6 Contact Us
9.7 Disclaimer

1.1 List of Tables
Table 1: COPD Therapeutics Market, Global, Licensing Deals Value, 2006-2017
Table 2: COPD Therapeutics Market, Global, Co-development Deals Value, 2006-2017
Table 3: COPD Therapeutics Market, Global, All Pipeline Products, Discovery, 2017
Table 4: COPD Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016
Table 5: COPD Therapeutics Market, Global, All Pipeline Products, Phase I, 2017
Table 6: COPD Therapeutics Market, Global, All Pipeline Products, Phase I, 2017
Table 7: COPD Therapeutics Market, Global, All Pipeline Products, Phase III, 2017
Table 8: COPD Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2016
Table 9: COPD Therapeutics Market, Asia-Pacific, Market Forecast, 2016-2023
Table 10: COPD Therapeutics Market, India, Market Forecast, 2016-2023
Table 11: COPD Therapeutics Market, China, Market Forecast, 2016-2023
Table 12: COPD Therapeutics Market, Australia, Market Forecast, 2016-2023
Table 13: COPD Therapeutics Market, South Korea, Market Forecast, 2016-2023
Table 14: COPD Therapeutics Market, Japan, Market Forecast, 2016-2023

1.2 List of Figures
Figure 1: COPD Therapeutics Market, Treatment Algorithm of COPD
Figure 2: COPD Market, Global, Moderate-to-Severe COPD Marketed Products Heatmap, Efficacy and Safety, 2017
Figure 3: COPD Market, Global, Very Severe COPD Marketed Products Heatmap, Efficacy and Safety, 2017
Figure 4: COPD Therapeutics Market, Global, Pipeline, 2017
Figure 5: COPD Therapeutics Market, Global, Pipeline by Molecular Target, 2017
Figure 6: Pipeline for COPD Therapeutics by Molecular Target and Stage of Development, Global, 2017
Figure 7: COPD Therapeutics Market, APAC, Mepolizumab Market ($m), 2019-2023
Figure 8: COPD Therapeutics Market, APAC, Benralizumab Market ($m), 2020-2023
Figure 9: COPD Therapeutics Market, APAC, PT003 Market ($m), 2018-2023
Figure 10: COPD Therapeutics Market, APAC, PT010 Market ($m), 2019-2023
Figure 11: COPD Therapeutics Market, APAC, FF/UMEC/VI Market ($m), 2018-2023
Figure 12: COPD Therapeutics Market, APAC, CHF-5993 Market ($m), 2020-2023
Figure 13: COPD Market, Global, Pipeline Heatmap, Efficacy, 2017
Figure 14: COPD Therapeutics Market, Global, Competitor Matrix for Efficacy and Safety of Marketed and Pipeline Products, 2017
Figure 15: COPD Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006-2016
Figure 16: COPD Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2006-2016
Figure 17: COPD Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2006-2016
Figure 18: COPD Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006-2016
Figure 19: COPD Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2006-2016
Figure 20: COPD Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2006-2016
Figure 21: COPD Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2006-2016
Figure 22: COPD Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2006-2016
Figure 23: COPD Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2006-2016
Figure 24: COPD Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 25: COPD Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
Figure 26: COPD Therapeutics Market, Asia-Pacific, Treatment Patterns (million) and Market Size ($bn), 2016-2023
Figure 27: COPD Therapeutics Market, India, Treatment Patterns (million), 2016-2023
Figure 28: COPD Therapeutics Market, India, Annual Cost of Therapy ($), 2016-2023
Figure 29: COPD Therapeutics Market, India, Market Size ($m), 2016-2023
Figure 30: COPD Therapeutics Market, China, Treatment Patterns (million), 2016-2023
Figure 31: COPD Therapeutics Market, China, Annual Cost of Therapy ($), 2016-2023
Figure 32: COPD Therapeutics Market, China, Market Size ($bn), 2016-2023
Figure 33: COPD Therapeutics Market, Australia, Treatment Patterns (million), 2016-2023
Figure 34: COPD Therapeutics Market, Australia, Annual Cost of Therapy ($), 2016-2023
Figure 35: COPD Therapeutics Market, Australia, Market Size ($m), 2016-2023
Figure 36: COPD Therapeutics Market, South Korea, Treatment Patterns (million), 2016-2023
Figure 37: COPD Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2016-2023
Figure 38: COPD Therapeutics Market, South Korea, Market Size ($m), 2016-2023
Figure 39: COPD Therapeutics Market, Japan, Treatment Patterns (million), 2016-2023
Figure 40: COPD Therapeutics Market, Japan, Annual Cost of Therapy ($), 2016-2023
Figure 41: COPD Therapeutics Market, Japan, Market Size ($m), 2016-2023
Figure 42: COPD Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2017
Figure 43: COPD Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2017
Figure 44: COPD Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017
Figure 45: COPD Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2017
Figure 46: COPD Therapeutics, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006-2017
Figure 47: COPD Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2006-2017
Figure 48: COPD Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2017
Figure 49: COPD Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017
Figure 50: COPD Therapeutics Market, Global, Co-development Deals by Molecule type and Stage of Development, 2006-2017
Figure 51: COPD Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006-2017

発刊日

2017/12/01

体裁

PDF / 120ページ

販売価格

4,995USD

発行

GBI Research

備考

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。他のライセンス形態・価格に関しましてはご相談下さい。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

関連カテゴリ

疾病別治療・領域別治療

購入・お問い合わせ

このレポートを購入

詳細を問い合わせる


PAGE